CMV-Related Hemorrhagic Retinal Vasculitis in a Multiple Myeloma Patient on Daratumumab Therapy: A Case Report
Patients with MM on daratumumab are at increased risk of opportunistic reactivations including CMV, potentially due to daratumumab's immunomodulatory side effects. Our patient developed CMV-related hemorrhagic retinal vasculitis despite low-dose acyclovir, which provides limited protection against CMV reactivation in CMV seropositive individuals. This case report therefore offers casuistic support for ophthalmic screening for CMV reactivation or CMV prophylaxis with letermovir in this patient population.
Authors
- Alexander Kaplan
- Miguel Cruz-Pimentel (ORCID: https://orcid.org/0000-0003-0581-7514)
- Vishal Kukreti (ORCID: https://orcid.org/0000-0002-1681-3837)
- Kirill Zaslavsky (ORCID: https://orcid.org/0000-0002-0286-8669)
- Peng Yan (ORCID: https://orcid.org/0000-0003-3818-9788)
- Matthaeus Ware
- Yasmin Motekalem
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- Princess Margaret Cancer Centre (CA)
- Health Net (US)
- Kensington Health (CA)
- SickKids Foundation (CA)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1080/09273948.2024.2432554
- Citations
- 3
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.16